Danish biotech firms surpass Swedish ones

In the past few years Danish biotech firms have been surpassing Swedish firms in the race to attract venture capital. According to a report from CBS Research Centre on Biotech Business. In 2004 small Danish “drug discovery” firms got twice as much investment as the equivalent Swedish firms. The report also showed that productivity in Denmark from 1997-2004 was 1.4 times more than in Sweden measured in terms of patent production.

“The capital input has been more per employee in these firms considered to be high risk and difficult to manage. There is a direct connection between input of capital and patent production as well as projects” says Professor Finn Valentin in an interview with Børsen on November 21st.

Download the report:
Structure, employment and performance in biotech firms: Comparison of Danish and Swedish drug discovery firms by Finn Valentin, Henrich Dahlgren and Rasmus Lund Jensen, Research Centre on Biotech Business her